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Abstract
In this opinion, the EFSA Panel on Genetically Modified Organisms (GMO Panel) assessed the
three-event stack maize MON 87427 9 MON 89034 9 NK603 and its three subcombinations,
independently of their origin. The GMO Panel has previously assessed the three single events
combined to produce this three-event stack maize and did not identify safety concerns. No new data
on the single events, leading to modification of the original conclusions on their safety, were identified.
Based on the molecular, agronomic, phenotypic and compositional characteristics, the combination of
the single maize events and of the newly expressed proteins in the three-event stack maize did not
give rise to issues regarding food and feed safety or nutrition. In the case of accidental release of
viable grains of maize MON 87427 9 MON 89034 9 NK603 into the environment, the three-event
stack maize would not raise environmental safety concerns. The GMO Panel concludes that the three-
event stack maize is as safe and as nutritious as the non-GM comparator and the tested non-GM
reference varieties in the context of its scope. The GMO Panel considered that its previous conclusions
on the two-event stack maize MON 89034 9 NK603 remain valid. For the two maize subcombinations
for which no experimental data were provided the GMO Panel assessed the likelihood of interactions
among the single events, and concluded that their combination would not raise safety concerns. These
two subcombinations are therefore expected to be as safe as the single events, the previously
assessed maize MON 89034 9 NK603 and maize MON 87427 9 MON 89034 9 NK603. Since the
post-market environmental monitoring plan for the three-event stack maize does not include any
provisions for the two subcombinations not previously assessed, the GMO Panel recommended the
applicant to revise the plan accordingly.
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Summary
Following the submission of application EFSA-GMO-BE-2013-117 under Regulation (EC) No 1829/2003
from Monsanto Company (referred to hereafter as the applicant), the Panel on Genetically Modified
Organisms of the European Food Safety Authority(EFSA) (referred to hereafter as GMO Panel) was
asked to deliver a Scientific Opinion on the safety of genetically modified glyphosate tolerant and
insect resistant maize MON 87427 9 MON 89034 9 NK603 (referred to hereafter as ‘three-event stack
maize’) and its subcombinations independently of their origin (referred to hereafter as ‘subcombinations’)
according to the Commission Implementing Regulation (EU) No 503/2013. The scope of application
EFSA-GMO-BE-2013-117 is for the placing on the market of maize MON 87427 9 MON 89034 9 NK603
and subcombinations MON 87427 9 MON 89034, MON 87427 9 NK603 and MON 89034 9 NK603
independently of their origin for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of two of the events present in the three-
event stack maize. The safety of subcombinations occurring as segregating progeny in the harvested
grains of maize MON 87427 9 MON 89034 9 NK603 is evaluated in the context of the assessment of
the three-event stack maize in Section 3.3 of the present GMO Panel Scientific Opinion. The safety of
subcombinations that have either been, or could be produced by conventional crossing through
targeted breeding approaches, and which can be bred, produced and marketed independently of the
three-event stack maize, are risk assessed in Section 3.4 of the present GMO Panel Scientific Opinion.
In delivering its Scientific Opinion, the GMO Panel considered the data available on the single
events, the three-event stack maize and a subcombination, the scientific comments submitted by the
Member States and the relevant scientific literature. The three-event stack maize was produced by
conventional crossing to combine three single maize events: MON 87427, expressing the
5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein for tolerance to glyphosate-
containing herbicides; MON 89034, expressing the Cry1A.105 and Cry2Ab2 proteins which confer
resistance to specific lepidopteran pests; and NK603, expressing the CP4 EPSPS protein and its variant
CP4 EPSPS L214P for tolerance to glyphosate-containing herbicides.
The GMO Panel evaluated the three-event stack maize and its subcombinations with reference to
the scope and appropriate principles described in its guidelines for the risk assessment of GM plants
and derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring of GM plants. The GMO Panel Guidance Documents establish the principle
that where all single events have been assessed, the risk assessment of stacked events should focus
mainly on issues related to (a) stability of the inserts, (b) expression of the introduced genes and their
products and (c) potential synergistic or antagonistic effects resulting from the combination of the
events (EFSA GMO Panel, 2011a).
For application EFSA-GMO-BE-2013-117, the previous assessments of the three single maize events
(MON 87427, MON 89034 and NK603) and of the two-event stack maize MON 89034 9 NK603
provided a basis to evaluate the three-event stack maize and its subcombinations. Maize MON 87427,
MON 89034, NK603 and MON 89034 9 NK603 were previously assessed by the GMO Panel and no
concerns on their safety were identified. No safety issue concerning the three single maize events was
identified by the updated bioinformatic analyses, nor reported by the applicant since the publication of
the previous GMO Panel Scientific Opinions. Therefore, the GMO Panel considers that its previous
conclusions on the safety of the single maize events remain valid.
For the three-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analyses of
agronomic, phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food/feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and post-market
environmental monitoring plans was also undertaken.
The molecular data establish that the events stacked in maize MON 87427 9 MON 89034 9 NK603
have retained their integrity. Protein expression analyses showed that the levels of the newly
expressed proteins are similar in the three-event stack maize and in the single events or, in the case of
CP4 EPSPS, show expected changes resulting from the combination of the MON 87427 and NK603
single events, both producing the CP4 EPSPS protein. No indications of interactions that may affect the
integrity of the events and the levels of the newly expressed proteins in the three-event stack maize
were identified.
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No relevant differences requiring further assessment for food/feed safety or environmental impact
were identified between maize MON 87427 9 MON 89034 9 NK603 and the non-GM comparator in
grain and forage composition and in agronomic and phenotypic characteristics.
Based on the molecular, agronomic, phenotypic and compositional characteristics, the combination
of maize events MON 87427, MON 89034 and NK603 in the three-event stack maize did not give rise
to issues regarding food and feed safety and nutrition. The combination of the newly expressed
proteins in the three-event stack maize did not raise concerns for human and animal health.
Considering the combined events, the outcome of the comparative analysis, the routes of exposure
and limited exposure levels, the GMO Panel concludes that the three-event stack maize would not raise
safety concerns in the event of accidental release of viable GM maize grains into the environment,
irrespective of possible interactions between the individual events within the three-event stack maize.
The GMO Panel concludes that the three-event stack maize is as safe and as nutritious as the non-GM
comparator and the tested non-GM reference varieties in the context of the scope of this application.
Since no new safety concerns were identified for the previously assessed two-event stack maize
MON 89034 9 NK603 and no new data leading to modification of the original conclusions on safety
were identified, the GMO Panel considers that its previous conclusions on this subcombination remain
valid. For the two subcombinations MON 87427 9 MON 89034 and MON 87427 9 NK603, for which
no experimental data were provided, the GMO Panel assessed the possibility of interactions between
the events, and concluded that different combinations of the events MON 87427, MON 89034 and
NK603 would not raise safety concerns. These two subcombinations are therefore expected to be as
safe as the single maize events, the previously assessed two-event stack maize and the three-event
stack maize MON 87427 9 MON 89034 9 NK603.
Given that no safety concerns were identified for food and feed derived from maize MON
87427 9 MON 89034 9 NK603 and its subcombinations MON 89034 9 NK603, MON 87427 9 MON
89034 and MON 87427 9 NK603, the GMO Panel considers that post-market monitoring of these
products is not necessary. However, the post-market environmental monitoring (PMEM) plan submitted
by the applicant for the three-event stack maize does not include any provisions for the two
subcombinations that were not previously assessed. Therefore, the GMO Panel recommends the
applicant to revise the plan accordingly.
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1. Introduction
1.1. Background
On 13 September 2013, the European Food Safety Authority (EFSA) received from the Competent
Authority of Belgium application EFSA-GMO-BE-2013-117, for authorisation of genetically modified
(GM) insect resistant and glyphosate tolerant maize MON 87427 9 MON 89034 9 NK603 (referred to
hereafter as ‘three-event stack maize’), submitted by Monsanto Europe S.A./N.V. (referred to hereafter
as the applicant) within the framework of Regulation (EC) No 1829/20031, for food and feed uses,
import and processing. The risk assessment of application EFSA-GMO-BE-2013-117 presented here is
for the placing on the market of the three-event stack maize and its subcombinations,2 independently
of their origin, for food and feed uses, import and processing.
After receiving application EFSA-GMO-BE-2013-117 and in accordance with Articles 5(2)(b) and 17
(2)(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and the European
Commission, and made the summary of the application available to the public on the EFSA website.3
EFSA initiated a formal review of the application to check compliance with the requirements laid down
in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. EFSA requested additional information
under completeness check on 25 October 2013 and 13 December 2013 and received it on 22
November 2013 and 20 December 2013, respectively. On 22 January 2014, EFSA declared the
application valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003. The
clock of the application was stopped from 28 January 2014 to 27 May 2015 due to the pending
assessment of the single-event maize MON 87427 (application reference EFSA-GMO-BE-2012-110).
EFSA made the valid application available to Member States and the European Commission, and
consulted nominated risk assessment bodies of Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC4 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003, to request their scientific opinion. Member States had
3 months after the date of receipt of the valid application (until 11 September 20155) to make their
opinion known.
The GMO Panel carried out the scientific risk assessment of the three-event stack maize and
subcombinations MON 87427 9 MON 89034, MON 87427 9 NK603 and MON 89034 9 NK603
(referred to as ‘subcombinations independently of their origin’ according to the Commission
Implementing Regulation (EU) No 503/20136). The GMO Panel requested additional information from
the applicant on 16 June 2015, 15 September 2015, 15 December 2015, 9 November 2016 and 6 April
2017. The applicant provided the requested information on 1 September 2015, 1 October 2015, 17
June 2016, 12 December 2016 and 6 June 2017, respectively. The applicant provided additional
information spontaneously on 13 December 2016.
In the frame of contracts OC/EFSA/UNIT/GMO/2013/01 and OC/EFSA/UNIT/GMO/2014/01, the
contractors performed preparatory work and delivered reports on the methods applied by the applicant
in performing bioinformatic analyses and statistical analyses, respectively.
In giving its Scientific Opinion to the European Commission, Member States and the applicant, and
in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has endeavoured
to respect a time limit of 6 months from the acknowledgement of the valid application. As additional
information was requested by the GMO Panel, the time limit of 6 months was extended accordingly, in
line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation, and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified
food and feed. Official Journal of the European Communities, L 268, 1–23.
2 The subcombinations are MON 87427 9 MON 89034, MON 87427 9 NK603 and MON 89034 9 NK603.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2013-00765
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
5 The Member States’ commenting period of application EFSA-GMO-BE-2013-117 was suspended until the clock of the
application was re-started following the adoption of the Scientific Opinion of application EFSA-GMO-BE-2012-110 (authorisation
of GM maize MON 87427).
6 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L 157, 8.6.2013, p. 1–48.
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1.2. Terms of Reference as provided by the requestor
The GMO Panel was asked to carry out a scientific assessment of ‘maize MON 87427 9
MON 89034 9 NK603 and all subcombinations of the individual events independently of their origin (as
present in the segregating progeny as well as independent stacks to be placed on the market as
such)’, for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of
Regulation (EC) No 1829/2003. The risk assessment of application EFSA-GMO-BE-2013-117 presented
here is for the placing on the market of glyphosate tolerant and insect resistant maize
MON 87427 9 MON 89034 9 NK603 and subcombinations, independently of their origin, for food and
feed uses, import and processing.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or specific conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identification of the specific transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientific opinion, the GMO Panel took into account application EFSA-GMO-BE-2013-
117, additional information provided by the applicant, scientific comments submitted by the Member
States and relevant scientific publications.
2.2. Methodologies
The GMO Panel carried out a scientific risk assessment of maize MON 87427 9 MON 89034 9
NK603 and its subcombinations MON 87427 9 MON 89034, MON 87427 9 NK603 and MON 89034 9
NK603, independently of their origin (Table 1), for food and feed uses, import and processing in
accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003. The GMO Panel took into
account the appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed (EFSA GMO Panel, 2011a), for the environmental risk assessment (ERA) of GM
plants (EFSA GMO Panel, 2010a) and for the post-market environmental monitoring (PMEM) of GM
plants (EFSA GMO Panel, 2011b).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion3 and
were taken into consideration during the scientific risk assessment.
3. Assessment
3.1. Introduction
Application EFSA-GMO-BE-2013-117 covers the three-event stack maize MON 87427 9
MON 89034 9 NK603 and its subcombinations MON 87427 9 MON 89034, MON 87427 9 NK603 and
MON 89034 9 NK603 independently of their origin (Table 1). The scope of this application is for food
and feed uses, import and processing, and excludes cultivation within the European Union (EU).
The term ‘subcombination’ refers to any combination of two of the events present in the three-
event stack maize.
The safety of subcombinations occurring as segregating progeny in the harvested grains of maize
MON 87427 9 MON 89034 9 NK603 is evaluated in the context of the assessment of the three-event
stack maize in Section 3.3 of the present GMO Panel Scientific Opinion.
‘Subcombination’ also covers combinations of two of the three events MON 87427,
MON 89034 or NK603 that have either been or could be produced by conventional crossing through
targeted breeding approaches (EFSA GMO Panel, 2011a). These are maize stacks that can be bred,
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produced and marketed independently of the three-event stack maize. These stacks are risk assessed
in Section 3.4 of this GMO Panel Scientific Opinion.
The three-event stack maize was produced by conventional crossing to combine three single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein), MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins) and NK603 (expressing the
CP4 EPSPS protein and the variant CP4 EPSPS L214P).
Herbicidal tolerance traits are achieved by the expression of CP4 EPSPS protein and its variant CP4
EPSPS L214P from Agrobacterium sp. strain CP4. Insect resistant traits are achieved by the expression
of the Cry1A.105 and Cry2Ab2 proteins from Bacillus thuringiensis subsp. kurstaki and subsp. aizawai,
which confer protection against specific lepidopteran pests (e.g. Ostrinia nubilalis (European corn
borer)).
The single maize events MON 87427, MON 89034, NK603 and the two-event stack maize
MON 89034 9 NK603 have been previously assessed by the GMO Panel (Table 2), and no safety
concerns were identified.
EFSA guidance establishes the principle that ‘For GM plants containing a combination of
transformation events (stacked events) the primary concern for risk assessment is to establish that the
combination of events is stable and that no interactions between the stacked events, that may raise
safety concerns compared to the single events, occur. The risk assessment of GM plants containing
stacked events focuses on issues related to: (a) stability of the inserts, (b) expression of the
introduced genes and their products and (c) potential synergistic or antagonistic effects resulting from
the combination of the events’ (EFSA GMO Panel, 2011a).
3.2. Updated information on the events
Since the publication of the scientific opinions on the single maize events by the GMO
Panel (Table 2), no safety issue concerning the three single events has been reported by the applicant.
Updated bioinformatic analyses on the junction regions for events MON 87427, MON 89034 and
NK603 confirmed that no known endogenous genes were disrupted by any of the inserts.7 Updated
bioinformatic analyses of the amino acid sequence of the newly expressed CP4 EPSPS, Cry1A.105 and
Cry2Ab2 proteins revealed no significant similarities to toxins and allergens.7 In addition, updated
bioinformatics analyses of the newly created open reading frames (ORFs) within the inserts and at
their junctions for events MON 87427, MON 89034 and NK603 to identify any ORFs with significant
similarity to toxins or allergens that were not previously assessed revealed that, for event MON 89034,
a single ORF exceeded the allergenicity assessment threshold of 35% identity using an 80 amino acid
Table 1: Two- and three-event maize stacks covered by the scope of application EFSA-GMO-BE-
2013-117
Degree of
stacking
Events Unique identifiers
Three-event
stack maize
MON 87427 9 MON 89034 9 NK603 MON–87427–7 9 MON–89Ø34–3 9 MON–ØØ6Ø3–6
Two-event
stack maize
MON 89034 9 NK603 MON–89Ø34–3 9 MON–ØØ6Ø3–6
MON 87427 9 MON 89034 MON–87427–7 9 MON–89Ø34–3
MON 87427 9 NK603 MON–87427–7 9 MON–ØØ6Ø3–6
Table 2: Single maize events and two-event stack maize previously assessed by the GMO Panel
Event Application or mandate EFSA Scientific Opinion
MON 87427 EFSA-GMO-BE-2012-110 EFSA GMO Panel (2015)
MON 89034 EFSA-GMO-NL-2007-37 EFSA (2008)
MON 89034 9 NK603 EFSA-GMO-NL-2007-38 EFSA GMO Panel (2009)
NK603 CE/ES/00/01
EFSA-GMO-NL-2005-22
EFSA-GMO-RX-NK603
EFSA (2004), EFSA (2007)
EFSA (2009)
EFSA (2009)
7 Additional information: 17/6/2016.
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sliding window approach.7 This ORF is found within the transcriptional unit of the Cry2Ab2 coding
sequence driven by the Figwort Mosaic Virus 35S promoter. It is in the same orientation but in a
different reading frame than the Cry2Ab2 ORF and does not contain any in-frame translational start
codon.8 In conclusion, these analyses indicated that the expression of an ORF showing significant
similarities to toxins or allergens for any of the events in maize MON 87427 9 MON 89034 9 NK603 is
highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis to microbial DNA for events MON 87427,
MON 89034 and NK603.7 The likelihood and potential consequences of plant-to-bacteria gene transfer
are described in Section 3.3.4.2.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Risk assessment of the three-event stack maize MON 87427 3 MON
89034 3 NK603
3.3.1. Molecular characterisation
Possible interactions affecting the integrity of the events, protein expression levels or the biological
functions conferred by the individual inserts are considered.
3.3.1.1. Genetic elements and their biological function9
Maize events MON 87427, MON 89034 and NK603 were combined by conventional crossing to
produce event MON 87427 9 MON 89034 9 NK603. The structure of the inserts introduced into maize
MON 87427, MON 89034 and NK603 is described in detail in the respective EFSA scientific opinions
(Table 2) and no new genetic modifications were involved. Genetic elements in the expression
cassettes of the single events are summarised in Table 3.
Intended effects of the inserts in maize MON 87427 9 MON 89034 9 NK603 are summarised in
Table 3.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry1A.105 and Cry2Ab2 proteins in
susceptible insects.
Table 3: Genetic elements in the expression cassettes of the events stacked in maize
MON 87427 9 MON 89034 9 NK603
Event Promoter 50 UTR Transit peptide Coding region Terminator
MON 87427 35S
(CaMV)
– CTP2
(Arabidopsis
thaliana)
CP4 epsps
(Agrobacterium sp.)
nos
(Agrobacterium
tumefaciens)
MON 89034 35S
(CaMV)
CAB
(Triticum sp.)
– cry1A.105
(B. thuringiensis)
Hsp17
(Triticum sp)
35S
(FMV)
– CTP
(Zea mays)
cry2Ab2
(B. thuringiensis)
nos
(A. tumefaciens)
NK603 act1
(Oryza sativa)
– CTP2
(A. thaliana)
CP4 epsps
(Agrobacterium sp.)
nos
(A. tumefaciens)
35S
(CaMV)
– CTP2
(A. thaliana)
CP4 epsps L214P
(Agrobacterium sp.)
nos
(A. tumefaciens)
CaMV: cauliflower mosaic virus; UTR: untranslated region; CTP: chloroplast transit peptide.
(–): When no element was specifically introduced to optimise expression.
8 Additional information: 6/6/2017.
9 Dossier: Part II – Section A2.2.2.
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3.3.1.2. Integrity of the events in the three-event stack maize MON 87427 3 MON
89034 3 NK6039
The genetic stability of the inserted DNA over multiple generations in the single maize events
MON 87427, MON 89034 and NK603 was demonstrated previously (Table 2). Integrity of these events
in maize MON 87427 9 MON 89034 9 NK603 was demonstrated by Southern analyses.
3.3.1.3. Information on the expression of the inserts10
CP4 EPSPS, Cry1A.105 and Cry2Ab2 protein levels were analysed by enzyme-linked immunosorbent
assay (ELISA) in material harvested from replicated field trials at five locations in the USA in the 2010
growing season. Samples analysed included leaf (V2–V4), grain (R6), pollen (pollination), root (V2–V4
and R5), whole plant (V10–V12) and forage (R5) both those treated and not treated with glyphosate.
Since grain and forage are the main raw commodities used for food and feed purposes, protein levels
in these commodities from maize MON 87427 9 MON 89034 9 NK603 (the highest mean values,
regardless of the treatment) are summarised in Table 5.
Table 4: Characteristics and intended effects of the events stacked in maize MON 87427 9
MON 89034 9 NK603
Event Protein Donor organism and biological function Intended effects in GM plant
MON 87427 CP4
EPSPS
Based on a gene from Agrobacterium strain
CP4. 5-enolpyruvylshikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic amino
acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Expression of the bacterial CP4 EPSPS
protein in maize MON 87427 confers
tolerance to glyphosate-containing
herbicides as it has lower affinity
towards glyphosate than the plant
endogenous enzyme
MON 89034 Cry1A.105
Cry2Ab2
Based on a gene from Bacillus thuringiensis
subsp. kurstaki and subsp. aizawai. B.
thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998)
Based on a gene from B. thuringiensis subsp.
kurstaki. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry)
genes
Event MON 89034 expresses a modified
Bacillus thuringiensis
Cry1A-type protein with overall amino
acid sequence identity of 93.4%, 90%
and 76.7% to the Cry1Ac, Cry1Ab and
Cry1F, respectively. Cry1A.105 is a
protein toxic to certain lepidopteran
larvae feeding on maize
Event MON 89034 expresses also the
Cry2Ab2, a protein toxic to certain
lepidopteran larvae feeding on maize
NK603 CP4
EPSPS
Based on a gene from Agrobacterium strain
CP4. 5-enolpyruvylshikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic amino
acid biosynthesis in plants and
microorganisms
The bacterial CP4 EPSPS protein
expressed in maize NK603 confers
tolerance to glyphosate-containing
herbicides as it has lower affinity
towards glyphosate than the plant
endogenous enzyme
CP4
EPSPS
L214P
Donor organism: Agrobacterium sp. strain
CP4.
5-enopyruvylshikimate-3-phosphate synthase
(EPSPS) is an enzyme involved in the shikimic
acid pathway for aromatic amino acid
biosynthesis in plants and microorganisms
Event NK603 expresses also CP4 EPSPS
L214P – this variant, compared to the
CP4 EPSPS protein, contains a single
amino acid substitution from leucine to
proline at position 214. The two CP4
EPSPS protein variants are structurally
and functionally equivalent
10 Dossier: Part II – Section A2.2.3; additional information: 17/6/2016.
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In order to assess the changes in protein expression levels which may result from potential
interactions between the events, protein levels were determined for the three-event stack maize and
the corresponding single events in different parts of the plant.
The levels of all the newly expressed proteins in the three-event stack maize and the corresponding
singles were similar in all tissues, except for the expected difference for the CP4 EPSPS protein levels
resulting from the combination of single events MON 87427 and NK603 both producing CP4 EPSPS
protein in the three-event stack maize (Appendix A). Therefore, there is no indication of interactions
that may affect the levels of the newly expressed proteins in this stack.
3.3.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in maize MON 87427 9 MON 89034 9 NK603
have retained their integrity. Protein expression analyses showed that the levels of the newly
expressed proteins are similar in the three-event stack maize and in the single events except for CP4
EPSPS, which showed in general the expected higher levels in the stack resulting from the combination
of the single events MON 87427 and NK603. Therefore, there is no indication of an interaction that
may affect the integrity of the events and the levels of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, the only foreseen
interactions at the biological level are between the Cry1A.105 and Cry2Ab2 proteins in susceptible
insects, which will be dealt with in Section 3.3.4.
3.3.2. Comparative analysis
3.3.2.1. Choice of comparator and production of material for the comparative analysis11
Application EFSA-GMO-BE-2013-117 presents data on agronomic and phenotypic characteristics, as
well as on forage and grain composition, of the three-event stack maize MON 87427 9 MON 89034 9
NK603 derived from field trials performed at nine sites in the USA during the 2010 growing season.
Seven field trials were used to collect both agronomic and phenotypic characteristics and tissues for
the compositional analysis, while the two remaining trial sites were used to collect only one set of data
each (agronomic and phenotypic characteristics or composition) (Table 6).
The three-event stack maize MON 87427 9 MON 89034 9 NK603 was obtained by conventional
crossing of the three single events. Event MON 87427 was introgressed in the inbred line LH198, while
events MON 89034 and NK603 were introgressed in LH287. As documented by the pedigree, the three
single events, after backcrossing, were combined in a hybrid maize with a genetic background (F1) of
LH198 9 LH287. The same two inbred lines (LH198 9 LH287) were crossed to produce the non-GM
Table 5: Means, standard deviation and ranges of protein levels (lg/g dry weight) in grain (n = 20)
and forage (n = 20) from maize MON 87427 9 MON 89034 9 NK603
Tissue/Developmental Stage Protein MON 87427 3 MON 89034 3 NK603
Grain (R6) CP4 EPSPS(a) 9.2(b)  1.5(c)
(6.2–12)(d)
Cry1A.105 4.4  0.85
(3.3–6.2)
Cry2Ab2 1.6  0.38
(1.2–2.5)
Forage (R5) CP4 EPSPS 170  45
(93–240)
Cry1A.105 19  5.3
(11–31)
Cry2Ab2 17  5.4
(9.0–30)
(a): CP4 EPSPS levels in the maize MON 87427 9 MON 89034 9 NK603 are the sum of two protein variants, CP4 EPSPS
(expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
(b): Mean.
(c): Standard deviation.
(d): Range.
11 Dossier: Part II – Sections A3.1 and A3.2; additional information: 1/9/2015 and 17/6/2016.
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hybrid maize used as comparator (MPA636B). On the basis of the provided pedigree, the GMO
Panel considers that MPA636B is a suitable non-GM comparator.
Field trials for the agronomic, phenotypic and compositional analysis of the three-event stack maize
MON 87427 9 MON 89034 9 NK603 were conducted in major maize growing areas in the USA,
representing regions of diverse agronomic practices and environmental conditions. At each site, the
following materials were grown in a randomised complete block design with four replicates: the three-
event stack maize MON 87427 9 MON 89034 9 NK603, the non-GM comparator (MPA636B) and four
non-GM maize reference varieties, all treated (sprayed) with plant protection products (PPP) according
to local requirements, and the three-event stack maize MON 87427 9 MON 89034 9 NK603 treated
with glyphosate in addition to PPP. Across all the sites, nineteen and twenty-two non-GM maize
reference varieties were used for the agronomic and phenotypic characterisation and for the
compositional analysis, respectively (Table 6).
Statistical analysis of field trials data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2010 field
trials followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, EFSA GMO Panel,
2011a). This includes, for each of the two treatments of maize MON 87427 9 MON 89034 9 NK603,
the application of a difference test (between the GM maize and the non-GM comparator) and an
equivalence test (between the GM maize and the set of non-GM commercial reference varieties). The
results of the equivalence test are categorised into four possible outcomes (I–IV, ranging from
equivalence to non-equivalence).12
3.3.2.2. Agronomic and phenotypic characteristics13
The agronomic and phenotypic characteristics evaluated on the basis of data collected from the
eight field trial sites in the USA during the 2010 growing season (Table 6) were: early stand count,
days to 50% pollen shed, days to 50% silking, stay green, ear height, plant height, dropped ear
count, stalk lodging, root lodging, final stand count, grain moisture, test weight, yield and endpoints
related to environmental interactions (abiotic stressors, disease damage and arthropod damage).
The three-event stack maize MON 87427 9 MON 89034 9 NK603 not treated with glyphosate
showed a statistically significant increase in ear height, plant height and stalk lodging, and a
reduction in grain moisture. Ear height, plant height and grain moisture fell within the equivalence
limits established by the non-GM reference varieties (equivalence category I), while for stalk lodging
equivalence with the non-GM reference varieties was more likely than not (equivalence category II).
Table 6: Overview of comparative analysis studies for the three-event stack maize MON 87427 9
MON 89034 9 NK603
Study focus Study details Comparator
Commercial non-GM
maize reference
varieties(a)
Agronomic and phenotypic
analysis
Field trials, 2010, USA, eight
locations(b)
Maize
MPA636B
Nineteen(c)
Compositional analysis Field trials, 2010, USA, eight
locations(d)
Maize
MPA636B
Twenty-two(e)
GM: Genetically modified.
(a): Four different varieties were grown at each location.
(b): Jackson County, Arkansas; Clinton County, Illinois; Cumberland County, Illinois; Stark County, Illinois; Pawnee County,
Kansas; Shelby County, Missouri; York County, Nebraska; and Miami County, Ohio.
(c): NC+ 5411; Burrus 645; DKC61-50; DKC62-30; Fielder’s Choice NG6778; Fontanelle 4924; H-9180; Kruger K-0210; Legacy
L6600; Lewis 6014; Lewis 7007; Midland Phillips 799; Midland Phillips 7B15P; Midwest Genetics 78130; Mycogen 2M746;
NK N72-G8; Pioneer 32B81; Stewart S588; and Triumph 1416.
(d): Jackson County, Arkansas; Clinton County, Illinois; Jefferson County, Iowa; Stark County, Illinois; Pawnee County, Kansas;
Shelby County, Missouri; York County, Nebraska; and Miami County, Ohio.
(e): Burrus 645; Cornbelt 96043; DKC61-50; DKC62-30; Fielder’s Choice NG6778; Fontanelle 4924; H-9180; Kruger K-0210;
Legacy L6600; Legacy L6673; Lewis 6014; Lewis 7007; Midland Phillips 799; Midland Phillips 7B15P; Midwest Genetics
78130; Mycogen 2M746; NC+ 5411; NK N72-G8; Pioneer 32B81; Stewart S518; Stewart S588; and Triumph 1416.
12 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
13 Dossier: Part II – Section A3.4; additional information: 1/9/2015 and 17/6/2016.
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For root lodging, a significant increase was observed but the endpoint could not be categorised for
equivalence because the variation between the non-GM reference varieties was estimated to be
zero.14
The three-event stack maize MON 87427 9 MON 89034 9 NK603 treated with glyphosate showed
a statistically significant increase in ear and plant height. Both endpoints fell within the equivalence
limits established by the non-GM reference varieties (equivalence category I).15
Given the magnitude of the observed differences, the outcomes of the equivalence test and the
nature of the endpoints, the GMO Panel considered that none of the differences in agronomic and
phenotypic characteristics between the three-event stack maize MON 87427 9 MON 89034 9 NK603
and the non-GM comparator were relevant for further assessment.
3.3.2.3. Compositional analysis16
Forage and grain harvested from the field trials in the USA in 2010 (Table 6) were analysed for 79
constituents (9 in forage and 70 in grain), including the key constituents recommended by the OECD
(OECD, 2002). For 14 grain constituents,17 more than 50% of the observations were below the limit of
quantification (LOQ). The statistical analysis was applied to the remaining 65 constituents (9 in
forage18 and 56 in grain19).
The results of the statistical analysis were the following:
• For maize MON 87427 9 MON 89034 9 NK603 (not treated with glyphosate), statistically
significant differences with the non-GM comparator were identified for 42 grain endpoints.20 All
the endpoints fell under equivalence category I or II except for levels of carbohydrates
(category III) and calcium (category IV) (Table 7).
• For maize MON 87427 9 MON 89034 9 NK603 (treated with glyphosate), statistically
significant differences with the non-GM comparator were identified for 16 grain endpoints and 2
forage endpoints.21 All the endpoints fell under equivalence category I or II except for calcium
levels (category IV) (Table 7).
14 Estimated mean values for ear height (cm): 107.1 (GM maize) and 103.4 (non-GM comparator). Estimated mean values for
plant height (cm): 229.1 (GM maize) and 222.6 (non-GM comparator). Estimated mean values for grain moisture (%): 14.6
(GM maize) and 14.9 (non-GM comparator). Estimated mean values for stalk lodging (plants/plot): 3.8 (GM maize) and 1.8
(non-GM comparator). Estimated mean values for root lodged (plants/plot): 1.7 (GM maize) and 0.4 (non-GM comparator).
15 Estimated mean values for ear height (cm): 106.6 (GM maize) and 103.4 (non-GM comparator). Estimated mean values for
plant height (cm): 229.0 (GM maize) and 222.6 (non-GM comparator).
16 Dossier: Part II – Section A3.3; additional information: 31/8/2015 and 12/12/2016.
17 Furfural and the fatty acids caprylic (C8:0), capric (C10:0), lauric (C12:0), myristic (C14:0), myristoleic (C14:1), pentadecanoic
(C15:0), pentadecenoic (C15:1), heptadecenoic (C17:1), c-linolenic (C18:3), eicosadienoic (C20:2), eicosatrienoic (C20:3),
arachidonic (C20:4) and erucic (C22:1).
18 Protein, moisture, ash, calcium, phosphorus, carbohydrates by calculation, total fat, acid detergent fibre (ADF) and neutral
detergent fibre (NDF)
19 Proximates (moisture, protein, total fat, ash and carbohydrates by calculation), fibre fractions (acid detergent fibre (ADF),
neutral detergent fibre (NDF) and total dietary fibre (TDF)), amino acids (alanine, arginine, aspartic acid, cystine, glutamic
acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine
and valine), fatty acids (palmitic (C16:0), palmitoleic (C16:1), heptadecanoic (C17:0), stearic (C18:0), oleic (C18:1), linoleic
(C18:2), linolenic (C18:3), arachidic (C20:0), eicosenoic (C20:1) and behenic (C22:0)) , vitamins (folic acid, niacin, b-carotene,
thiamin, riboflavin, pyridoxine and a-tocopherol) , minerals (calcium, copper, iron, magnesium, manganese, phosphorus,
potassium, sodium and zinc) and other compounds (raffinose, ferulic acid, p-coumaric acid and phytic acid).
20 The grain constituents with significantly different levels were ash, protein, total fat, carbohydrates by calculation, NDF,
calcium, phosphorus, copper, iron, magnesium, manganese, potassium, zinc, alanine, arginine, aspartic acid, cystine, glutamic
acid, glycine, histidine, isoleucine, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine,
palmitoleic acid (C16:1), oleic acid (C18:1), linoleic acid (C18:2), stearic acid (C18:0), arachidic acid (C20:0), b-carotene,
thiamin, a-tocopherol, raffinose, ferulic acid, p-coumaric acid and phytic acid.
21 The forage constituents with significantly different levels were moisture and calcium. The grain constituents with significantly
different levels were ADF, ash, calcium, magnesium, manganese, phosphorus, zinc, arginine, glycine, stearic acid (C18:0),
niacin, a-tocopherol, ferulic acid and p-coumaric acid.
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The GMO Panel assessed all the compositional differences between maize MON 87427 9
MON 89034 9 NK603 and the non-GM comparator. After considering the known biological role of the
compounds, the outcome of the equivalence test (Table 7) and the magnitude of the changes
observed, the GMO Panel did not identify any need for further food/feed safety assessment.
3.3.2.4. Conclusions of the comparative analysis
The GMO Panel concludes that none of the differences identified in forage and grain composition
between maize MON 87427 9 MON 89034 9 NK603 and the non-GM comparator, and none of those
identified in the agronomic and phenotypic characteristics, needs further assessment regarding food
and feed safety.
Based on the agronomic and phenotypic characteristics of the three-event stack maize
MON 87427 9 MON 89034 9 NK603, none of the differences observed between maize MON 87427 9
MON 89034 9 NK603 and the non-GM comparator are further assessed for potential environmental
impact.
3.3.3. Food and feed safety assessment
3.3.3.1. Effects of processing
Processed products22
Maize MON 87427 9 MON 89034 9 NK603 will undergo existing production processes used for
conventional maize. No novel production process is envisaged. Based on the outcome of the comparative
assessment, processing of the three-event stack maize MON 87427 9 MON 89034 9 NK603 into food
and feed products is not expected to result in products being different from those of conventional
non-GM maize varieties.
Newly expressed proteins23
The effects of heat treatment on the newly expressed proteins Cry1A.105, Cry2Ab2, CP4 EPSPS
(including the variant CP4 EPSPS L214P) have been previously assessed by the GMO Panel in the
context of the single maize events (Table 2).
3.3.3.2. Toxicology
Toxicological assessment of newly expressed proteins24
Three proteins (Cry1A.105, Cry2Ab2 and CP4 EPSPS, including its variant CP4 EPSPS L214P) are
newly expressed in the three-event stack maize MON 87427 9 MON 89034 9 NK603 (Section 3.3.1).
Table 7: Compositional endpoints from grain that were further considered based on the results of
the statistical analysis: means (for the GM maize and the non-GM comparator) and
equivalence limits (from the non-GM commercial reference varieties) estimated from USA
2010 field trials data
Endpoint
Non-GM
comparator
Maize
MON 87427 3 MON 89034 3 NK603
Equivalence limits from
non-GM reference
varietiesNot treated(a) Treated(b)
Carbohydrates
(by calculation)
(% DM)
86.1 87.05* 86.16 (84.89, 86.95)
Calcium
(mg/kg DM)
480 510* 530* (270, 490)
DM: dry matter.
For the GM maize, significantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by greyscale backgrounds: white (equivalence category I), light grey (equivalence category III) and dark grey
(equivalence category IV).
(a): Treated with conventional herbicides only.
(b): Treated with conventional herbicides and with glyphosate.
22 Dossier: Part II – Section A3.5.
23 Dossier: Part II – Section A4.2.3.
24 Dossier: Part II – Section A4.2.
Scientific opinion on application EFSA-GMO-BE-2013-117
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2017;15(8):4922
The GMO Panel has previously assessed these proteins in the context of the single events (Table 2),
and no safety concerns were identified. The GMO Panel is of the opinion that no scientific data have
emerged which call for a change of this conclusion.
The CP4 EPSPS proteins are enzymes acting on the shikimic acid pathway for the biosynthesis of
aromatic amino acids in plants, showing high substrate specificity. The two insecticidal proteins
(Cry1A.105 and Cry2Ab2) act through cellular receptors found in target insect species, and it is
reported that the gastrointestinal tract of mammals, including humans, lacks receptors with high
specific affinity to Cry proteins (Hammond et al., 2013; Koch et al., 2015).
On the basis of the known biological function of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions relevant to food and feed safety between the
newly expressed proteins.
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins Cry1A.105, Cry2Ab2, CP4 EPSPS and its variant CP4 EPSPS L241P in the
three-event stack maize MON 87427 9 MON 89034 9 NK603.
Toxicological assessment of components other than newly expressed proteins25
The three-event stack maize does not show any compositional difference with the non-GM
comparator that would require further toxicological assessment (Section 3.3.2).
3.3.3.3. Animal studies with the food/feed derived from GM plants26
No animal studies with food/feed derived from maize MON 87427 9 MON 89034 9 NK603 were
provided by the applicant (e.g. 90-day toxicity studies in rodents or feeding studies in young rapidly
growing animal species).
No substantial modifications in the composition of maize MON 87427 9 MON 89034 9 NK603
(Section 3.3.2), no indication of possible unintended effects and no indication of interactions relevant
for food/feed safety were identified. Therefore, animal studies on the food/feed derived from maize
MON 87427 9 MON 89034 9 NK603 are not required (EFSA GMO Panel, 2011a).
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a). In addition, when known functional aspects of the newly expressed protein or
structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins27
For allergenicity, the GMO Panel has previously evaluated the safety of the proteins Cry1A.105,
Cry2Ab2 and CP4 EPSPS (including the variant CP4 EPSPS L214P) individually, and no concerns on
allergenicity were identified in the context of the applications assessed (Table 2). No new information
on allergenicity of these proteins that might change the previous conclusions of the GMO Panel has
become available. Based on the current knowledge, and as none of the newly expressed proteins
showed allergenicity, no reasons for concerns regarding the simultaneous presence of these newly
expressed proteins in this three-event stack maize affecting their allergenicity were identified.
For adjuvanticity, proteins derived from B. thuringiensis (Bt proteins) have been suggested to
possess adjuvant activity based on animal studies on Cry1Ac when applied at relatively high doses
(e.g. Vazquez et al., 1999). The GMO Panel has previously evaluated the safety of the Cry1A.105 and
Cry2Ab2 proteins and no concerns on adjuvanticity in the context of the applications assessed were
identified (Table 2). The levels of Bt proteins in this three-event stack maize are similar to those in the
respective single maize events (Table 5). From the limited experimental evidence available, the
GMO Panel did not find indications that the presence of the Bt proteins at the levels expressed in this
25 Dossier: Part II – Section A4.3.
26 Dossier: Part II – Section A4.5.
27 Dossier: Part II – Sections A5.1 and A5.3.
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three-event stack maize might act as adjuvants with the potential to enhance a specific
immunoglobulin E (IgE) response and to favour the development of an allergic reaction.
Assessment of allergenicity of GM plant products28
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize has not been considered to be a common allergenic food29 (OECD, 2002). Therefore, the
GMO Panel did not request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (Sections 3.3.1, 3.3.2 and
3.3.3.2), the GMO Panel identified no indications of a potentially increased allergenicity of food and feed
derived from the three-event stack maize with respect to that derived from the non-GM comparator.
3.3.3.5. Nutritional assessment of GM food/feed30
The intended traits of maize MON 87427 9 MON 89034 9 NK603 are insect resistance and
herbicide tolerance, with no intention to alter nutritional parameters. Comparison of nutrients
and anti-nutrients of maize MON 87427 9 MON 89034 9 NK603 with the non-GM comparator and
reference varieties did not identify differences that would require further safety assessment. From
these data, the GMO Panel concludes that the nutritional impact of food and feed derived from maize
MON 87427 9 MON 89034 9 NK603 is similar to that expected from the non-GM comparator and
non-GM commercial reference varieties.
3.3.3.6. Conclusion of the food and feed safety assessment
The three newly expressed proteins in the three-event stack maize MON 87427 9
MON 89034 9 NK603 (Cry1A.105, Cry2Ab2 and CP4 EPSPS, including its variant CP4 EPSPS L214P) do
not raise safety concerns for human and animal health. No interactions between these proteins
relevant for food and feed safety were identified. Similarly, the GMO Panel did not identify indications
of safety concerns regarding allergenicity or adjuvanticity related to the presence of the newly
expressed proteins in maize MON 87427 9 MON 89034 9 NK603, or regarding the overall allergenicity
of the three-event stack maize. Maize MON 87427 9 MON 89034 9 NK603 is as nutritious as the
non-GM comparator and the non-GM commercial varieties tested.
3.3.4. Environmental risk assessment
Considering the scope of application EFSA-GMO-BE-2013-117 (which excludes cultivation), the ERA of
the three-event stack maize MON 87427 9 MON 89034 9 NK603 is mainly concerned with: (1) the
exposure of bacteria to recombinant DNA in the gastrointestinal tract of animals fed GM material and
bacteria present in environments exposed to faecal material of these animals (manure and faeces); and
(2) the accidental release into the environment of viable maize MON 87427 9 MON 89034 9 NK603
grains during transportation and/or storage and processing (EFSA GMO Panel, 2010a).
3.3.4.1. Persistence and invasiveness of the GM plant31
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the European environment without appropriate management. Occasional feral GM maize
plants may occur outside cultivation areas (e.g. Han et al., 2015; Pascher, 2016), but survival is limited
mainly by a combination of low competitiveness, absence of a dormancy phase and susceptibility to
plant pathogens, herbivores and cold climate conditions. In fields within the EU, maize volunteers may
arise under some environmental conditions (mild winters). Field observations indicate that maize grain
may survive and overwinter in some regions, resulting in volunteers in subsequent crops (e.g. Gruber
et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers in the EU have been
shown to grow weakly and flower asynchronously with the maize crop (Palaudelmas et al., 2009).
28 Dossier: Part II – Section A5.2.
29 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
30 Dossier: Part II – Section A6.
31 Dossier: Part II - Section E3.1.
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As described in Section 3.3.2, field trials were carried out in the USA in the 2010 growing season to
assess the agronomic and phenotypic characteristics of the three-event stack maize in comparison with
the non-GM comparator. The data showed no changes in agronomic and phenotypic characteristics
that would indicate altered fitness, persistence and invasiveness of the three-event stack maize. The
GMO Panel considers that the persistence and invasiveness of the three-event stack maize
MON 87427 9 MON 89034 9 NK603 compared to conventional maize remains unchanged.
Considering the agronomic and phenotypic data on the three-event stack maize and the general
characteristics of maize described above, there are no indications of an increased likelihood of
establishment and spread of occasional feral GM maize plants harbouring any combination of the three
events of which it is composed. Should these plants be exposed to glyphosate-containing herbicides or
infested by insect pests that are susceptible to the Cry1A.105 or Cry2Ab2 proteins, they are likely to
exhibit a selective advantage that could increase their local occurrence. However, considering maize
vulnerability to several abiotic and biotic factors, this occurrence is expected to be transient and will
not result in different environmental impacts compared to conventional maize.
In addition to the data presented by the applicant, the GMO Panel is not aware of any scientific
report of increased spread, establishment and survival capacity of the three-event stack maize
MON 87427 9 MON 89034 9 NK603 or maize with comparable properties.
Therefore, the GMO Panel concludes that it is unlikely that the three-event stack maize
MON 87427 9 MON 89034 9 NK603 would differ from conventional maize varieties in its ability to
survive until subsequent seasons under European environmental conditions, if there was accidental
release of viable GM maize grains into the environment. The occurrence of GM maize plants in the
environment will thus be limited. Further, the occurrence of GM maize plants will not result in different
environmental impacts compared to conventional maize.
3.3.4.2. Potential for gene transfer32
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene flow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
The potential for HGT of the recombinant DNA of the single events has been assessed in previous
GMO Panel Scientific Opinions (Table 2) and no concern as a result of an unlikely, but theoretically
possible, HGT of the recombinant genes to bacteria in the gut of animal fed GM material or other
receiving environments was identified. The applicant submitted an updated bioinformatic analysis for
each of the single events in order to assess possibility for HGT by HR.7
Bioinformatic analysis of event MON 87427 revealed two elements that could provide sufficient
length and sequence identity which could facilitate HGT, i.e. the truncated left border of an
Agrobacterium tumefaciens octopine plasmid and the T-nos terminator of an A. tumefaciens nopaline
plasmid. Because these elements are located on different plasmids, the results of the bioinformatic
analyses give no indication for facilitated double HR.
Bioinformatic analysis of event MON 89034 revealed three elements that could provide sufficient
length and sequence identity which could facilitate HGT. These are the truncated left border at 30 and
the one at 50 and the T-nos terminator. The homologies with A. tumefaciens at the left borders align to
the same region of the target sequences in an A. tumefaciens octopine plasmid but are inserted in the
plant genome in an opposite orientation. Therefore they are supporting double HR. The T-nos
terminator gives homology with an A. tumefaciens nopaline plasmid and does not support double HR.
Bioinformatic analysis of the NK603 event revealed sequence identity with the two copies of the
T-nos terminator from an A. tumefaciens nopaline Ti plasmid present in the same orientation. This
increases the likelihood of insertion of the CP4 epsps gene in the nopaline synthase terminator of the
Ti plasmid. This insertion would affect the production of nopaline after transfer of the T-DNA to the
plant and would hamper the development of crown gall tumour and the further spread of this
recombinant plasmid in the environment. Moreover this insertion will result in the integration of a plant
codon optimised version of the CP4 epsps gene that is expected to be less efficiently translated in
bacteria.
32 Dossier: Part II - Sections E3.1 and E3.2.
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Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage, were not
identified.
Based on the above information, the GMO Panel did not identify an increased likelihood for
horizontal transfer of recombinant genes to bacteria for the three-event stack maize. This is consistent
with its previous assessment of maize events MON 87427, MON 89034 and NK603.
Plant-to-plant gene transfer
Considering the scope of application EFSA-GMO-BE-2013-117 and the biology of maize, the
potential for occasional feral GM maize plants originating from grain import spills to transfer
recombinant DNA to sexually cross-compatible plants is assessed. As pointed out above
(Section 3.3.4.1), the occurrence of feral GM maize plants is expected to be limited.
The extent of cross-pollination from occasional feral GM maize to other maize species will mainly
depend on accidental release during transportation and processing and on successful establishment
and subsequent flowering of the GM maize plant. For maize, vertical gene transfer is limited to Zea
species. Populations of sexually compatible wild relatives of maize outside cultivation are not known in
Europe (Eastham and Sweet, 2002; OECD, 2003), therefore vertical gene transfer is not considered to
be an environmental issue in the EU.
The flowering of occasional feral GM maize plants originating from accidental release during
transportation and processing is unlikely to lead to dispersal of significant amounts of GM maize pollen
onto other maize plants. Field observations performed on maize volunteers after GM maize cultivation
in Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that
cross-pollinated neighbouring plants only at low levels (Palaudelmas et al., 2009). Thus, the likelihood
of cross-pollination between cultivated maize and the occasional feral maize plants resulting from grain
spillage is considered extremely low.
In conclusion, even if cross-pollination would occur, the GMO Panel is of the opinion that the
likelihood of environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties.
3.3.4.3. Interactions of the GM plant with target organisms33
Interactions might occur between different Cry proteins. Whether such an interaction takes place
depends on the arthropod species (EcoƩtat, 2014; De Schrijver et al., 2015). Considering the scope of
application EFSA-GMO-BE-2013-117, potential interactions with target organisms of occasional feral
three-event stack maize MON 87427 9 MON 89034 9 NK603 plants arising from grain import spills
are not considered a relevant issue by the GMO Panel.
3.3.4.4. Interactions of the GM plant with non-target organisms34
As mentioned in Section 3.3.4.3, interactions between Cry proteins, leading to synergistic
insecticidal effects, might occur in other susceptible non-target species. Considering that environmental
exposure of non-target organisms to stored GM grains, spilled GM grains or GM plants arising from
spilled GM grains is limited, potential exposure of non-target organisms sensitive to Cry1A.105 and/or
Cry2Ab2 proteins is likely to be very low.
The GMO Panel also evaluated whether the expressed Cry1A.105 and Cry2Ab2 proteins might affect
non-target organisms by entering the environment through faecal material of animals fed GM maize.
Cry proteins are degraded by enzymatic activity in the gastrointestinal tract, meaning that only low
amounts of intact Cry proteins would remain in the faeces. This was demonstrated for Cry1Ab
(Einspanier et al., 2004; Lutz et al., 2005; Lutz et al., 2006; Wiedemann et al., 2006; Guertler et al.,
2008; Paul et al., 2010). Further degradation of the protein in manure and faeces will take place
because of microbiological proteolytic activity. In addition, there will be further degradation of Cry
proteins in soil, reducing the possibility for exposure of potentially sensitive non-target organisms.
Although Cry proteins may bind to clay minerals and organic substances in soil, thereby reducing their
availability to microorganisms for degradation, there are no indications of persistence and
accumulation of Cry proteins from GM crops in soil (Gruber et al., 2012; Valldor et al., 2015). The GMO
Panel is not aware of evidence of released Cry proteins from GM plants causing significant negative
effects on soil inhabiting organisms.
33 Dossier : Part II – Section E3.3.
34 Dossier : Part II – Section E3.4.
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Considering the scope of the application, it can be concluded that the exposure of potentially
sensitive non-target organisms to the Cry1A.105 and Cry2Ab2 proteins is likely to be very low and the
risk related to interactions with non-target organisms is therefore of no relevance.
3.3.4.5. Interactions with the abiotic environment and biogeochemical cycles35
Considering the scope of application EFSA-GMO-BE-2013-117 and the low level of exposure to the
environment, potential interactions of spilled grains or occasional feral maize MON 87427 9
MON 89034 9 NK603 with the abiotic environment and biogeochemical cycles are not considered a
relevant issue by the GMO Panel.
3.3.4.6. Conclusion of the environmental risk assessment
There are no indications of an increased likelihood of establishment and spread of occasional feral
three-event stack maize MON 87427 9 MON 89034 9 NK603 plants in the case of accidental release
into the environment of viable grains, unless these plants are infested by insect pests that are
susceptible to the Cry1A.105 and/or Cry2Ab2 proteins or exposed to glyphosate-containing herbicides.
However, the GMO Panel is of the opinion that the possible exposure of feral GM plants to these
herbicides or susceptible pests would not result in different environmental impacts compared to
conventional maize. Considering the scope of application EFSA-GMO-BE-2013-117, interactions with the
biotic and abiotic environment are not considered to be relevant issues. Risks associated with an
unlikely but theoretically possible horizontal gene transfer of recombinant DNA from the three-event
stack maize to bacteria have not been identified. Therefore, considering the novel combination of
events, the introduced traits, the outcome of the comparative analysis, the routes of exposure and the
limited potential exposure levels, the GMO Panel concludes that the three-event stack maize
MON 87427 9 MON 89034 9 NK603 would not raise safety concerns in the event of accidental release
of viable GM maize grains into the environment.
3.3.5. Conclusion on the three-event stack maize MON 87427 3 MON 89034 3
NK603
No new data on the single maize events MON 87427, MON 89034 and NK603 leading to a
modification of the original conclusions on their safety were identified.
The combination of maize events MON 87427, MON 89034 and NK603 in the three-event stack
maize did not give rise to issues pertaining to the molecular, agronomic/phenotypic or compositional
characteristics of the three-event stack maize that would be of concern for food and feed safety and
nutrition.
The newly expressed proteins in the three-event stack maize do not raise safety concerns for
human and animal health and the environment in light of the scope of this application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identified in maize MON 87427 9
MON 89034 9 NK603. Comparison of the levels of the newly expressed proteins between the three-
event stack maize and those of the single maize events did not reveal an interaction at protein
expression level.
Considering the combined events and the outcome of the comparative analysis, the routes of
exposure and limited exposure levels, the GMO Panel concludes that the three-event stack maize
MON 87427 9 MON 89034 9 NK603 would not raise safety concerns in the event of accidental release
of viable GM maize grains into the environment.
No scientific information that could change the conclusions on this three-event stack maize was
retrieved in a literature search covering the period since the time of validity of the application. The
GMO Panel concludes that the three-event stack maize is as safe and as nutritious as the non-GM
comparator in the context of its scope.
3.4. Risk assessment of the subcombinations
The GMO Panel Guidance Documents establish the principle that where all single events have been
assessed, the risk assessment of stacked events focuses on issues related to: (a) stability of the
events; (b) expression of the events; and (c) potential interactions between the events (EFSA GMO
Panel, 2011a).
35 Dossier : Part II – Section E3.6.
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For the two subcombinations (maize MON 87427 9 MON 89034 and MON 87427 9 NK603) for
which no specific data have been submitted and which have not been previously assessed by the GMO
Panel, the risk assessment takes as its starting point the assessment of the single maize events, and
uses the data generated for the three-event stack maize, as well as all the additional data available on
subcombinations previously assessed by the GMO Panel.
3.4.1. Subcombination previously assessed
The two-event stack maize MON 89034 9 NK603 has been previously assessed by the GMO
Panel and no safety concerns were identified (EFSA GMO Panel, 2009). No new scientific information
relevant to the risk assessment of this two-event stack maize became available since the validation of
application EFSA-GMO-BE-2013-117. Consequently, the GMO Panel considers that its previous
conclusions on this subcombination remain valid.
3.4.2. Subcombinations not previously assessed
The two-event maize stacks MON 87427 9 MON 89034 and MON 87427 9 NK603 included in the
scope of this application have not been previously assessed by the GMO Panel. No experimental data
were provided for these two maize stacks.
3.4.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the three single maize events
was demonstrated previously (Table 2). Integrity of the events was demonstrated in the three-event
stack maize MON 87427 9 MON 89034 9 NK603 (Section 3.3.1) and in the two-event stack maize
MON 89034 9 NK603 (EFSA GMO Panel, 2009). The GMO Panel finds no reasons to expect the loss of
integrity of the events in the two-event maize stacks MON 87427 9 MON 89034 and MON 87427 9
NK603.
3.4.2.2. Expression of the events
The GMO Panel assessed whether any combination of the three events by conventional crossing
could result in significant changes in expression levels of the newly expressed proteins, as this could
indicate an unexpected interaction between the events. Based on current knowledge of the molecular
elements introduced, there is no reason to expect interactions that would affect the levels of the newly
expressed proteins in the two subcombinations compared with those in the single maize events. This
assumption was confirmed by comparing the levels of the newly expressed proteins of each single
maize event with those of the three-event stack maize. The levels were similar in the three-event stack
maize and in the single events except for CP4 EPSPS, which showed, in general, the expected higher
level in the stack resulting from the combination of the single events MON 87427 and NK603
(Section 3.3.1.3 and Appendix A). Therefore, there was no indication of an interaction at protein
expression level. In addition, expression data from the two-event stack maize MON 89034 9 NK603
were similar to those observed in each of the single maize events (EFSA GMO Panel, 2009). This
confirms that interactions affecting the expression levels of the newly expressed proteins are not
expected in the two subcombinations MON 87427 9 MON 89034 and MON 87427 9 NK603.
3.4.2.3. Potential interactions between the events
The GMO Panel assessed the potential interactions between events, due to their combination in the
two-event stacks MON 87427 9 MON 89034 and MON 87427 9 NK603, taking into consideration
intended traits and unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions between these proteins in maize MON 87427 9
MON 89034 or MON 87427 9 NK603 relevant for food/feed or environmental safety. The GMO
Panel took into account all the intended and potential unintended effects considered in the assessment
of the three single events, the two-event stack maize MON 890349 NK603 and the three-event stack
maize MON 87427 9 MON 89034 9 NK603. It was concluded that none of these effects would raise
safety concerns when combined in any of the two subcombinations.36 Therefore, the GMO Panel is of
the opinion that no additional data are needed to complete the assessment of subcombinations of the
three-event stack maize.
36 115th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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3.4.3. Conclusion
Since no new safety concerns were identified for the previously assessed two-event stack maize
MON 89034 9 NK603, the GMO Panel considers that its previous conclusions on this subcombination
remain valid. For the two subcombinations MON 87427 9 MON 89034 and MON 87427 9 NK603, for
which no experimental data have been provided, the GMO Panel assessed the possibility of interactions
between the events, and concluded that these combinations would not raise safety concerns. These
two subcombinations are therefore expected to be as safe as the single maize events, the previously
assessed two-event stack maize MON 890349 NK603 and the three-event stack maize
MON 87427 9 MON 89034 9 NK603.
3.5. Post-market monitoring
3.5.1. Post-market monitoring of GM food/feed
There was no indication that food/feed products derived from the three-event stack maize
MON 87427 9 MON 89034 9 NK603 are less safe or nutritious than those derived from the non-GM
comparator. Furthermore, the overall intake or exposure is not expected to change because of the
introduction of maize MON 87427 9 MON 89034 9 NK603 into the market. The two-event stack
maize MON 890349 NK603 has been previously assessed and no safety concerns were identified. The
subcombinations MON 87427 9 MON 89034 and MON 87427 9 NK603 are expected to be as safe as
the single maize events, the previously assessed two-event stack maize MON 890349 NK603 and the
three-event stack maize MON 87427 9 MON 89034 9 NK603. Therefore, the GMO Panel considers
that post-market monitoring of maize MON 87427 9 MON 89034 9 NK603 and its subcombinations is
not necessary.
3.5.2. Post-market environmental monitoring37
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC, are to: (1) confirm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the environmental risk assessment are correct and (2) identify the occurrence of adverse
effects of the GMO, or its use, on human health or the environment that were not anticipated in the
environmental risk assessment.
Monitoring is related to risk management, and thus a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific content of the PMEM
plan provided by the applicant (EFSA, 2006; EFSA GMO Panel, 2011b).
The PMEM plan proposed by the applicant includes: (1) the description of a monitoring approach
involving operators (federations involved in import and processing), reporting to the applicants, via a
centralised system, any observed adverse effect(s) of GMOs on human health and the environment; (2) a
coordinating system established by EuropaBio for the collection of information recorded by the various
operators (Lecoq et al., 2007; Windels et al., 2008); and (3) the review of relevant scientific publications
retrieved from literature searches. The applicant proposes to submit a PMEM report on an annual basis
and a final report at the end of the authorisation period. The GMO Panel considers that the scope of the
post-market environmental monitoring plan provided by the applicant is consistent with the scope of
maize MON 87427 9 MON 89034 9 NK603. As the ERA does not cover cultivation and did not identify
any potential adverse environmental effect from maize MON 87427 9MON 89034 9 NK603, no case-
specific monitoring is necessary. The GMO Panel agrees with the reporting intervals proposed by the
applicant in its PMEM plan. However, the PMEM plan submitted by the applicant for the three-event stack
maize does not include any provisions for the two subcombinations not previously assessed by the GMO
Panel. Therefore, the GMO Panel recommends the applicant to revise the plan accordingly.
4. Overall conclusions and recommendations
No new data on the three single maize events MON 87427, MON 89034 and NK603 that would lead
to a modification of the original conclusions on their safety were identified.
The combination of events MON 87427, MON 89034 and NK603 in the three-event stack maize did
not give rise to food/feed safety issues related to molecular, agronomic/phenotypic or compositional
characteristics. The newly expressed proteins in the three-event stack maize did not raise concerns for
37 Dossier: Part II – Section E4; additional information: 13/12/2016.
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human and animal health. Maize MON 87427 9 MON 89034 9 NK603 is expected to be as nutritious as
the non-GM comparator and the tested non-GM maize commercial reference varieties.
Considering the combined events, the outcome of the comparative analysis and the routes and
levels of exposure, the GMO Panel concludes that maize MON 87427 9 MON 89034 9 NK603 would
not raise environmental safety concerns in the event of accidental release of viable GM maize grains
into the environment.
The GMO Panel concludes that maize MON 87427 9 MON 89034 9 NK603 is as safe and as
nutritious as the non-GM comparator and the tested non-GM maize reference varieties in the context
of the scope of this application.
Since no new data on the previously assessed two-event stack maize MON 89034 9 NK603 that
would lead to a modification of the original conclusions on its safety were identified, the GMO
Panel considers that its previous conclusions on this two-event stack maize remain valid. For the two
subcombinations MON 87427 9 MON 89034 and MON 87427 9 NK603, for which no experimental
data have been provided, the GMO Panel assessed possible interactions between the events, and
concluded that combinations of the events MON 87427, MON 89034 and NK603 would not raise safety
concerns in these maize subcombinations. The two subcombinations are therefore expected to be as
safe and as nutritious as the single maize events, the previously assessed two-event stack maize
MON 89034 9 NK603 and the three-event stack maize MON 87427 9 MON 89034 9 NK603.
Given the absence of safety concerns for food and feed derived from the three-event stack maize
MON 87427 9 MON 89034 9 NK603 and its subcombinations MON 890349 NK603, MON 87427 9
MON 89034 and MON 87427 9 NK603, the GMO Panel considers that post-market monitoring of these
products is not necessary.
The GMO Panel considers that the scope of the PMEM plans provided by the applicant is consistent
with the scope of the three-event stack maize and the already assessed two-event stack maize
MON 89034 9 NK603. The GMO Panel agrees with the reporting intervals proposed by the applicant in
the PMEM plans. However, the PMEM plan submitted by the applicant for the three-event stack maize
does not include any provisions for the two subcombinations that were not previously assessed.
Therefore, the GMO Panel recommends the applicant to revise the plan accordingly.
Documentation as provided to EFSA
1) Letter from the Competent Authority of Belgium received on 13 September 2013
concerning a request for placing on the market of genetically modified maize MON
87427 9 MON 89034 9 NK603 submitted by Monsanto Europe S.A./N.V. in accordance
with Regulation (EC) No 1829/2003 (application reference EFSA-GMO-BE-2013-117).
2) Acknowledgement letter dated 24 September 2013 from EFSA to the Competent Authority
of Belgium.
3) Letter from EFSA to applicant dated 25 October 2013 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 22 November 2013 providing additional
information under completeness check.
5) Letter from EFSA to applicant dated 13 December 2013 requesting additional information
under completeness check.
6) Letter from applicant to EFSA received on 20 December 2013 providing additional
information under completeness check.
7) Letter from EFSA to applicant dated 22 January 2014 delivering the ‘Statement of Validity’
of application EFSA-GMO-BE-2013-117 for placing on the market of genetically modified
maize MON 87427 9 MON 89034 9 NK603 submitted by Monsanto Europe S.A./N.V. in
accordance with Regulation (EC) No 1829/2003.
8) Letter from EFSA to applicant dated 28 January 2014 stopping the clock due to single event
not finalised (MON 87427).
9) Letter from EFSA to applicant dated 4 June 2015 re-starting the clock on 27 May 2015 due
to finalisation of single event (MON 87427).
10) Letter from EFSA to applicant dated 16 June 2015 requesting additional information and
stopping the clock.
11) Letter from applicant to EFSA received on 1 September 2015 providing additional information.
12) Letter from EFSA to applicant dated 15 September 2015 requesting additional information
and maintaining the clock stopped.
Scientific opinion on application EFSA-GMO-BE-2013-117
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(8):4922
13) Letter from applicant to EFSA received on 1 October 2015 providing additional information.
14) Letter from EFSA to applicant dated 15 December 2015 requesting additional information
and maintaining the clock stopped.
15) Letter from applicant to EFSA received on 17 June 2016 providing additional information.
16) Email from EFSA to applicant dated 20 June 2016 re-starting the clock on 17 June 2016.
17) Letter from EFSA to applicant dated 9 November 2016 requesting additional information
and stopping the clock.
18) Letter from applicant to EFSA received on 12 December 2016 providing additional information.
19) Letter from applicant to EFSA received on 13 December 2016 providing additional information
spontaneously.
20) Email from EFSA to applicant dated 13 December 2016 re-starting the clock on 12
December 2016.
21) Email from applicant to EFSA, dated 11 January 2017 requesting clarifications.
22) Letter from EFSA to applicant, dated 13 January 2017 providing clarifications.
23) Email from applicant to EFSA, dated 25 January 2017 requesting clarifications.
24) Letter from EFSA to applicant, dated 31 January 2017 providing clarifications.
25) Email from applicant to EFSA, dated 3 March 2017 requesting clarifications.
26) Letter from EFSA to applicant dated 6 April 2017 requesting additional information and
stopping the clock.
27) Letter from applicant to EFSA received on 6 June 2017 providing additional information.
28) Email from EFSA to applicant dated 6 June 2017 re-starting the clock on 6 June 2017.
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Abbreviations
ADF acid detergent fibre
CaMV cauliflower mosaic virus
CTP chloroplast transit peptide
DNA deoxyribonucleic acid
DM dry matter
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
GM genetically modified
GMO genetically modified organism
GMO Panel EFSA Panel on Genetically Modified Organisms
HGT horizontal gene transfer
HR homologous recombination
IgE immunoglobulin E
LOQ limit of quantification
NDF neutral detergent fibre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PMEM post-market environmental monitoring
PPP plant protection products
TDF total dietary fibre
T-DNA transfer-deoxyribonucleic acid
UTR untranslated region
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize MON 87427 9 MON 89034 9 NK603 (treated with glyphosate),
MON 87427 (treated with glyphosate), NK603 (treated with glyphosate) and MON 89034 (not treated) from field trials performed in the USA in 2010
CP4 EPSPS Cry1A.105 Cry2Ab2
Tissue
(Developmental stage) Stack(a) MON 87427 NK603 Stack MON 89034 Stack MON 89034
Leaf (V2–V4) 890(b)270(c)
(470–1300)(d)
570  220
(250–970)
340  110
(130–480)
190  90
(51–280)
210  110
(49–370)
140  70
(53–330)
150  67
(57–260)
Grain (R6) 9.2  1.5
(6.2–12)
4.4  1.2
(2.9–7.6)
5.6  1.0
(3.8–7.3)
4.4  0.85
(3.3–6.2)
3.9  0.65
(2.7–5.6)
1.6  0.38
(1.2–2.5)
1.7  0.56
(0.47–3.1)
Pollen (pollination) 330  82
(130–460)
< LOQ(e) 350  76
(210–470)
6.8  1.6
(4.7–11)
8.4  7.5
(4.7–38)
0.60  0.61
(0.29–2.7)
0.78  0.50
(0.39–2.1)
Root (V2–V4) 180  73
(89–330)
230  62
(78–350)
160  90
(59–320)
41  12
(25–60)
47  12
(36–88)
61  14
(33–94)
50  12
(35–77)
Root (R5) 87  31
(33–130)
69  17
(38–100)
25  9.2
(10–39)
9.7  2.1
(5.9–13)
9.6  1.7
(6.8–14)
17  5.6
(6.2–25)
22  7.3
(5.1–36)
Whole Plant (V10–V12) 550  160
(340–880)
390  150
(65–650)
180  52
(93–270)
50  16)
(28–82)
61  18
(34–100)
25  9.0
(11–48)
32  15
(16–68)
Forage (R5) 170  45
(93–240)
120  23
(83–180)
56  13
(32–80)
19  5.3
(11–31)
21  5.8
(10–31)
17  5.4
(9.0–30)
19  5.1
(8.5–29)
(a): ‘Stack’ refers to maize MON 87427 9 MON 89034 9 NK603.
(b): Mean.
(c): Standard deviation.
(d): Range.
(e): LOQ: limit of quantification; due to specific insert design, little to no CP4 EPSPS protein is expected to be produced in pollen.
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